Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Aug 30:2011:0206.

Secondary prevention of ischaemic cardiac events

Affiliations

Secondary prevention of ischaemic cardiac events

Jane S Skinner et al. BMJ Clin Evid. .

Abstract

Introduction: Coronary artery disease is the leading cause of mortality in resource-rich countries, and is becoming a major cause of morbidity and mortality in resource-poor countries. Secondary prevention in this context is long-term treatment to prevent recurrent cardiac morbidity and mortality in people who have had either a prior acute myocardial infarction (MI) or acute coronary syndrome, or who are at high risk due to severe coronary artery stenoses or prior coronary surgical procedures. Secondary prevention in people with an acute MI or acute coronary syndrome within the past 6 months is not included.

Methods and outcomes: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of antithrombotic treatment; other drug treatments; cholesterol reduction; blood pressure reduction; non-drug treatments; and revascularisation procedures? We searched: Medline, Embase, The Cochrane Library, and other important databases up to May 2010 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).

Results: We found 137 systematic reviews or RCTs that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.

Conclusions: In this systematic review, we present information relating to the effectiveness and safety of the following interventions: advice to eat less fat, advice to eat more fibre, advice to increase consumption of fish oils, amiodarone, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers, angiotensin II receptor blockers plus ACE inhibitors, antioxidant vitamin combinations, antiplatelet agents, aspirin, beta-blockers, beta-carotene, blood pressure reduction, calcium channel blockers, cardiac rehabilitation including exercise, class I antiarrhythmic agents, coronary artery bypass grafting (CABG), fibrates, hormone replacement therapy (HRT), Mediterranean diet, multivitamins, non-specific cholesterol reduction, oral anticoagulants, oral glycoprotein IIb/IIIa receptor inhibitors, percutaneous coronary intervention (PCI), psychosocial treatment, smoking cessation, statins, vitamin C, and vitamin E.

PubMed Disclaimer

Similar articles

  • Heart failure.
    McKelvie RS. McKelvie RS. BMJ Clin Evid. 2011 Aug 30;2011:0204. BMJ Clin Evid. 2011. PMID: 21878135 Free PMC article.
  • Myocardial infarction (ST-elevation).
    Wakai AP. Wakai AP. BMJ Clin Evid. 2011 Jan 7;2011:0202. BMJ Clin Evid. 2011. PMID: 21477402 Free PMC article.
  • Myocardial infarction (ST-elevation).
    Wakai AP. Wakai AP. BMJ Clin Evid. 2009 Jan 9;2009:0202. BMJ Clin Evid. 2009. PMID: 19445779 Free PMC article.
  • Exercise-based cardiac rehabilitation for coronary heart disease.
    Dibben G, Faulkner J, Oldridge N, Rees K, Thompson DR, Zwisler AD, Taylor RS. Dibben G, et al. Cochrane Database Syst Rev. 2021 Nov 6;11(11):CD001800. doi: 10.1002/14651858.CD001800.pub4. Cochrane Database Syst Rev. 2021. PMID: 34741536 Free PMC article.
  • Heart failure.
    McKelvie RS. McKelvie RS. BMJ Clin Evid. 2010 Feb 25;2010:0204. BMJ Clin Evid. 2010. PMID: 21718583 Free PMC article.

Cited by

References

    1. American Heart Association. Heart disease and stroke statistics – 2004 update. Dallas, Texas: American Heart Association, 2004.
    1. Weisman SM, Graham DY. Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med 2002;162:2197–2202. - PubMed
    1. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. BMJ 2002;324:71–86. Search date 1997. - PMC - PubMed
    1. Serebruany VL, Malinin AI, Eisert RM, et al. Risk of bleeding complications with antiplatelet agents: meta-analysis of 338,191 patients enrolled in 50 randomized controlled trials. Am J Hematol 2004;75:40–47. - PubMed
    1. He J, Whelton PK, Vu B, et al. Aspirin and risk of hemorrhagic stroke. A meta-analysis of randomised controlled trials. JAMA 1998;280:1930–1935. - PubMed

Publication types